CGT Manufacturing Process Design

WEBINAR

Viral vector therapies are gaining increasing traction with more and more companies looking to take the leap from other biologics. In the early stages of clinical development, it’s expedient to outsource to de-risk the venture. For CGTs, this can be challenging because CDMO capacity is limited and the manufacturing complexity is higher than for other biologics. Nevertheless, experience in bioprocessing can be leveraged.

Understanding the similarities and differences between CGT and other biologics processes is crucial to design a facility. Comparisons will be made between mAb and viral vector facility layouts. Based on this, considerations for your strategy development will be explored.

In this webinar, you will learn:

• Key differences in viral vector vs. other biologics manufacturing processes
• How these differences translate to facility layout
• How to develop a strategy to increase your long-term business value